GuiZhou SanLi Pharmaceutical Co.,Ltd

Shanghai Stock Exchange 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd Revenue for the year ending December 31, 2023: USD 230.29 M

GuiZhou SanLi Pharmaceutical Co.,Ltd Revenue is USD 230.29 M for the year ending December 31, 2023, a 32.29% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

GuiZhou SanLi Pharmaceutical Co.,Ltd Revenue for the year ending December 31, 2022 was USD 174.08 M, a 17.80% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Revenue for the year ending December 31, 2021 was USD 147.77 M, a 53.05% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Revenue for the year ending December 31, 2020 was USD 96.55 M, a -23.92% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Revenue for the year ending December 31, 2019 was USD 126.91 M, a 20.83% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd

CEO	Mr. Hai Zhang
IPO Date	April 28, 2020
Location	China
Headquarters	Xiayun Industrial Park
Employees	2,282
Sector	Health Care
Industries Pharmaceuticals

Description

GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years